Version 2024
Replaced Code

2024 ICD-10-CM Diagnosis Code E20.8

Other hypoparathyroidism

ICD-10-CM Code:
E20.8
ICD-10 Code for:
Other hypoparathyroidism
Is Billable?
Not Valid for Submission
Chronic Condition Indicator: [1]
Chronic
Code Navigator:

Code Classification

  • Endocrine, nutritional and metabolic diseases
    (E00–E89)
    • Disorders of other endocrine glands
      (E20-E35)
      • Hypoparathyroidism
        (E20)

E20.8 is a non-specific and non-billable diagnosis code code, consider using a code with a higher level of specificity for a diagnosis of other hypoparathyroidism. The code is not specific and is NOT valid for the year 2024 for the submission of HIPAA-covered transactions. Category or Header define the heading of a category of codes that may be further subdivided by the use of 4th, 5th, 6th or 7th characters.

Specific Coding Applicable to Other hypoparathyroidism

Non-specific codes like E20.8 require more digits to indicate the appropriate level of specificity. Consider using any of the following ICD-10-CM codes with a higher level of specificity when coding for other hypoparathyroidism:

  • E20.81 for Hypoparathyroidism due to impaired parathyroid hormone secretion - NON-BILLABLE CODE

  • Use E20.810 for Autosomal dominant hypocalcemia - BILLABLE CODE

  • Use E20.811 for Secondary hypoparathyroidism in diseases classified elsewhere - BILLABLE CODE

  • Use E20.812 for Autoimmune hypoparathyroidism - BILLABLE CODE

  • Use E20.818 for Other specified hypoparathyroidism due to impaired parathyroid hormone secretion - BILLABLE CODE

  • Use E20.819 for Hypoparathyroidism due to impaired parathyroid hormone secretion, unspecified - BILLABLE CODE

  • Use E20.89 for Other specified hypoparathyroidism - BILLABLE CODE

Clinical Classification

Clinical Information

  • Hypoparathyroidism

    a condition caused by a deficiency of parathyroid hormone (or pth). it is characterized by hypocalcemia and hyperphosphatemia. hypocalcemia leads to tetany. the acquired form is due to removal or injuries to the parathyroid glands. the congenital form is due to mutations of genes, such as tbx1; (see digeorge syndrome); casr encoding calcium-sensing receptor; or pth encoding parathyroid hormone.
  • Acquired Hypoparathyroidism

    hypoparathyroidism, the cause of which is not present at birth.
  • Albright Hereditary Osteodystrophy with Multiple Hormone Resistance|PHP1a|Pseudohypoparathyroidism Type 1a

    parathyroid hormone (pth) resistance caused by heterozygous inactivating mutation(s) of the maternal allele of the gnas gene encoding gs-alpha, resulting in expression of pth from only the paternal allele. clinical manifestations include albright hereditary osteodystrophy, early-onset obesity, and, in some cases, resistance to thyroid-stimulating hormone, gonadotropins, and growth hormone-releasing hormone, reflecting additional manifestations of gs-alpha deficiency.
  • Albright Hereditary Osteodystrophy without Multiple Hormone Resistance|Albright Hereditary Osteodystrophy with Multiple Hormone Resistance|PPHP|Pseudopseudohypoparathyroidism

    a condition caused by inactivating mutation(s) in the paternal allele of the gnas gene, encoding gs-alpha, resulting in expression of the gs-alpha protein from only the maternal allele. affected individuals have the clinical phenotype of albright hereditary osteodystrophy without hormone resistance.
  • Albright's Hereditary Osteodystrophy|Albright Hereditary Osteodystrophy|Albright's Hereditary Osteodystrophy with Multiple Hormone Resistance|PHP1A|Pseudohypoparathyroidism, Type IA

    a rare, autosomal dominant syndrome caused by mutations in the gnas gene. it is characterized by the presence of short stature, obesity, round face, brachydactyly, subcutaneous ossifications, and pseudohypoparathtyroidism.
  • Autosomal Dominant Hypoparathyroidism

    hypoparathyroidism associated with heterozygous mutation(s) in the pth gene, which encodes parathyroid hormone, or in the gcm2 gene, which encodes chorion-specific transcription factor gcmb.
  • Autosomal Recessive Hypoparathyroidism

    hypoparathyroidism associated with homozygous mutation(s) in the pth gene, which encodes parathyroid hormone, or in the gcm2 gene, which encodes chorion-specific transcription factor gcmb.
  • Barakat Syndrome|Hypoparathyroidism, Deafness, and Renal Anomalies Syndrome

    a condition characterized by hypoparathyroidism, sensorineural deafness, and renal failure. it is related to autosomal dominant inactivating mutation(s) in gata3, encoding a transcription factor important for the embryonic development of the parathyroid gland, the auditory stem, and the kidneys.
  • Grade 1 Hypoparathyroidism, CTCAE|Grade 1 Hypoparathyroidism

    asymptomatic; clinical or diagnostic observations only; intervention not indicated
  • Grade 2 Hypoparathyroidism, CTCAE|Grade 2 Hypoparathyroidism

    moderate symptoms; medical intervention indicated
  • Grade 3 Hypoparathyroidism, CTCAE|Grade 3 Hypoparathyroidism

    severe symptoms; medical intervention or hospitalization indicated
  • Grade 4 Hypoparathyroidism, CTCAE|Grade 4 Hypoparathyroidism

    life-threatening consequences; urgent intervention indicated
  • Grade 5 Hypoparathyroidism, CTCAE|Grade 5 Hypoparathyroidism

    death
  • Hypoparathyroidism

    an endocrine disorder characterized by decreased production of parathyroid hormone by the parathyroid glands. it is usually caused by damage of the parathyroid glands during head and neck surgery. signs and symptoms include muscle cramps, abdominal pain, dry skin, brittle nails, cataracts, tetany, and convulsions.
  • Hypoparathyroidism, CTCAE|Hypoparathyroidism|Hypoparathyroidism

    a disorder characterized by a decrease in production of parathyroid hormone by the parathyroid glands.
  • Hypoparathyroidism-Retardation-Dysmorphism Syndrome|HRDS|Hypoparathyroidism with Short Stature, Mental Retardation, and Seizures|Hypoparathyroidism, Congenital, Associated with Dysmorphism, Growth Retardation, and Developmental Delay|Sanjad-Sakati Syndrome

    an autosomal recessive condition caused by mutation(s) in the tbce gene, encoding tubulin-specific chaperone e. it is characterized by congenital hypoparathyroidism, mental retardation, seizures and developmental delay.
  • Iatrogenic Hypoparathyroidism

    hypoparathyroidism resulting from medical treatment or intervention.
  • Parathyroid Hormone Resistance|Pseudohypoparathyroidism|Pseudoparathyroidism

    a finding indicating decreased tissue sensitivity to parathyroid hormone.
  • Primary Hypoparathyroidism

    abnormally low levels of parathyroid hormone due to a disorder originating within the parathyroid glands.
  • Pseudohypoparathyroidism

    a condition characterized by the insensitivity of the tissues to respond to the activity of the parathyroid hormone. it results in increased levels of parathyroid hormone in the serum, hypocalcemia, and hyperphosphatemia.
  • Renal Parathyroid Hormone Resistance|Pseudohypoparathyroidism Type 1b

    parathyroid hormone resistance caused by defects in methylation in the gnas gene that cause loss of expression of gs-alpha from the maternal allele in renal tissue, resulting in decreased phosphate excretion and increased calcium excretion. individuals with this condition may also have brachydactyly and partial resistance to thyroid-stimulating hormone.
  • Secondary Parathyroid Hormone Resistance|Acquired Parathyroid Hormone Resistance|Acquired Parathyroid Hormone Resistance|Pseudohypoparathyroidism, Type 2|Pseudohypoparathyroidism, Type 2

    parathyroid hormone (pth) resistance caused by vitamin d deficiency and characterized by clinically increased pth concentrations with relative hyperphosphatemia. the diagnosis can be confirmed by finding of a normal cyclic adenosine monophosphate (camp) response to pth infusion, but deficient phosphaturic response, indicating a defect distal to camp generation in renal cells.
  • TBCE wt Allele|HRD|Hypoparathyroidism, Growth and Mental Retardation, and Dysmorphism Gene|KCS|KCS1|Kenny-Caffey Syndrome Gene|PEAMO|Tubulin Folding Cofactor E wt Allele|pac2

    human tbce wild-type allele is located in the vicinity of 1q42.3 and is approximately 85 kb in length. this allele, which encodes tubulin-specific chaperone e protein, is involved in both tubulin folding and tubulin dimer dissociation. mutations in the gene are associated with progressive encephalopathy with amyotrophy and optic atrophy, hypoparathyroidism-retardation-dysmorphism syndrome and kenny-caffey syndrome 1.
  • Transient Neonatal Hypoparathyroidism

    a disorder of decreased production of parathyroid hormone by the parathyroid gland in a newborn. it is due to maternal hyperparathyroidism. it may be characterized by hypocalcemic seizures in the first weeks of life.
  • X-Linked Hypoparathyroidism|X-linked Hypoparathyroidism

    hypoparathyroidism in which the inheritance is recessive and linked to the q26-q27 region of the x chromosome. the parathyroid glands are usually incompletely developed (parathyroid dysgenesis) or absent (parathyroid agenesis).

New 2024 ICD-10-CM Code

E20.8 is new to ICD-10-CM code set for the FY 2024, effective October 1, 2023. The National Center for Health Statistics (NCHS) has published an update to the ICD-10-CM diagnosis codes which became effective October 1, 2023. This is a new and revised code for the FY 2024 (October 1, 2023 - September 30, 2024).

Replaced Code

This code was replaced in the 2024 ICD-10-CM code set with the code(s) listed below. The National Center for Health Statistics (NCHS) has published an update to the ICD-10-CM diagnosis codes which became effective October 1, 2023. This code was replaced for the FY 2024 (October 1, 2023 - September 30, 2024).


  • E20.810 - Autosomal dominant hypocalcemia
  • E20.811 - Secondary hypoparathyroidism in diseases classd elswhr
  • E20.812 - Autoimmune hypoparathyroidism
  • E20.818 - Oth hypoparathyroidism due to impaired PTH secretion
  • E20.819 - Hypoparathyroidism due to impaired PTH secretion, unsp
  • E20.89 - Other specified hypoparathyroidism

Convert E20.8 to ICD-9-CM

  • ICD-9-CM Code: 252.1 - Hypoparathyroidism
    Approximate Flag - The approximate mapping means there is not an exact match between the ICD-10 and ICD-9 codes and the mapped code is not a precise representation of the original code.

Patient Education


Parathyroid Disorders

Most people have four pea-sized glands, called parathyroid glands, on the thyroid gland in the neck. Though their names are similar, the thyroid and parathyroid glands are completely different. The parathyroid glands make parathyroid hormone (PTH), which helps your body keep the right balance of calcium and phosphorous.

If your parathyroid glands make too much or too little hormone, it disrupts this balance. If they secrete extra PTH, you have hyperparathyroidism, and your blood calcium rises. In many cases, a benign tumor on a parathyroid gland makes it overactive. Or, the extra hormones can come from enlarged parathyroid glands. Very rarely, the cause is cancer.

If you do not have enough PTH, you have hypoparathyroidism. Your blood will have too little calcium and too much phosphorous. Causes include injury to the glands, endocrine disorders, or genetic conditions. Treatment is aimed at restoring the balance of calcium and phosphorous.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases


[Learn More in MedlinePlus]

Code History

  • FY 2024 - Code Added, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.